AstraZeneca has unveiled strong 16% revenue growth for the year just gone, but price pressures from the US and China means this is expected to dip below 10% in 2025. That will make it more difficult for company to achieve its ambitious goal of hitting $80bn in revenues in 2030; there is still a long way from last year’s income of around $51bn.
But the most decisive factor here will be the hit rate for the company’s large late-stage pipeline
Key Takeaways
- AstraZeneca aims to launch 20 new drug in the 2024-2030 period, but can they all be blockbuster hits
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?